Last updated: May 14, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT07413354 | 2 | Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma | PD-1 + Herbal extract -- immune checkpoint inhibition combined with herbal immunomodulator (immune checkpoint inhibitor + herbal supplement) |
| NCT07580261 | 1 | YMN-A02 for Advanced Primary Hepatocellular Carcinoma. | Unknown mechanism |
| NCT04996914 | — | Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma | Unknown mechanism |
| NCT06794073 | — | Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study | PD-1 -- immune checkpoint inhibitor (Tislelizumab) combined with multi-kinase inhibitor (Lenvatinib) |
| NCT07226869 | — | Computer Guided Microwave Liver Ablation | Unknown mechanism |
| Sponsor | Recruiting trials |
|---|---|
| Sun Yat-sen University | 39 |
| Tianjin Medical University Cancer Institute and Hospital | 17 |
| Second Affiliated Hospital of Guangzhou Medical University | 16 |
| Fudan University | 16 |
| Tongji Hospital | 13 |
Countries/regions with the most active trial sites for hepatocellular carcinoma. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Aug 2026 | NCT07430202 | A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) | DNAJB1-PRKACA fusion kinase -- peptide vaccine plus glutamine antagonist plus PD-1 and CTLA-4 inhibitors |
| Jul 1, 2026 | NCT07365839 | Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma | PD-1 (Cemiplimab) +/- CTLA-4 (Fianlimab) -- immune checkpoint inhibitors |
| May 1, 2026 | NCT07446257 | THIO and Cadonilimab in Resectable Hepatocellular Carcinoma | PD-1 + nucleoside analog -- PD-1 inhibitor plus nucleoside analog |
| Apr 30, 2026 | NCT07522411 | Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma | PD-1 + VEGF + Chemotherapy -- immune checkpoint inhibitor + anti-angiogenic antibody + chemotherapy |
| Apr 14, 2026 | NCT07478302 | A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma | ROCK2 + VEGF -- kinase inhibitor plus anti-angiogenic antibody |
| Apr 10, 2026 | NCT07547553 | A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC | FGF19 -- monoclonal antibody |
| Apr 1, 2026 | NCT05842174 | Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma | Autophagy inhibition + embolization -- hydroxychloroquine plus lipiodol embolization |
| Apr 1, 2026 | NCT07075120 | Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer | CTLA-4 + PD-1 -- immune checkpoint inhibitors |
Want trials matched to a specific patient profile?
Enter biomarkers, stage, and prior treatments — get ranked trial matches with eligibility breakdown in minutes.
Find Matching TrialsSource: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.